TheBioTechReview
Industry Radar

Biotech Industry Trends 2026: The Shift from Scientific Discovery to Commercial Realism in Cell & Gene and mRNA Therapeutics

By Senior Technical/Financial Audit Journalist

Introduction: The Hidden Economic Logic Behind the Biotech Boom

The biopharmaceutical sector is approaching a structural inflection point. By the end of 2026, the cell and gene therapy (CGT) market is projected to reach $33.5 billion (Source 1: Towards Healthcare, January 2026), while the mRNA therapeutics market, valued at $17.25 billion in 2025, is forecast to surpass $83.49 billion by 2035 at a compound annual growth rate (CAGR) of 17.08% (Source 2: Nova One Advisor, December 2025). These headline figures, however, obscure a more consequential transformation: the industry is pivoting from discovery validation to operational execution.

The central question facing stakeholders is no longer whether these therapeutic platforms can produce clinical efficacy. Rather, the defining challenge has shifted to manufacturing scalability, delivery innovation, and regulatory de-risking. As one industry observer noted, "The hurdle has shifted from 'Will this medicine work?' to 'How can it be delivered to the patient?'" This transition—from scientific discovery to commercial realism—represents the core economic logic underpinning market projections through 2035.

Section 1: Cell & Gene Therapy – From Lab Validation to Supply Chain Viability

Market Structure and Segment Analysis

The CGT market's trajectory toward $33.5 billion in 2026, with a long-term forecast of $232 billion by 2035, is not uniformly distributed. The most demanding segments for innovation include oncology, cardiovascular, immunology, dermatology, and neurology (Source 1). Each therapeutic area presents distinct manufacturing and delivery challenges that directly impact scalability.

Oncology currently dominates CGT clinical pipelines, yet the highest growth potential resides in cardiovascular and immunology indications, where the patient population size is substantially larger. This demographic reality forces a recalibration of manufacturing economics: autologous therapies, which account for the majority of approved CGT products, face inherent cost constraints due to patient-specific production cycles. The industry's response has been a strategic pivot toward allogeneic and, increasingly, in vivo approaches.

The In Vivo CAR-T Milestone

A critical 2026 milestone is the transition of in vivo CAR-T therapies from preclinical to early clinical trials. This shift represents a fundamental redesign of the therapeutic value chain. Traditional ex vivo CAR-T requires leukapheresis, genetic modification, expansion, and reinfusion—a process taking weeks and costing approximately $373,000 to $475,000 per patient. In vivo CAR-T, by contrast, delivers genetic payloads directly into patients using lipid nanoparticles or viral vectors, potentially reducing manufacturing complexity and cost by an order of magnitude.

The operational implications are significant. Supply chains designed for cryogenic storage and just-in-time delivery of patient-specific products must be reconfigured for standardized, off-the-shelf inventory management. Early clinical data from in vivo CAR-T programs will determine whether these logistical advantages translate into comparable or superior efficacy profiles.

Regulatory De-Risking as Competitive Advantage

In this evolving landscape, regulatory de-risking has emerged as a distinct competitive advantage. Companies investing in early proof-of-concept data—including biodistribution studies, immunogenicity profiling, and off-target toxicity assessments—are positioning themselves to navigate increasingly stringent regulatory frameworks.

AstraZeneca's commitment to invest $15 billion in China through 2030 for CGT R&D exemplifies this strategy (Source 1). The investment targets early-stage proof-of-concept data generation, recognizing that regulatory approval timelines are compressed when developers present comprehensive preclinical packages. This approach reflects a broader industry recognition that the cost of regulatory failure in late-stage trials—where CGT programs face unique challenges related to persistence, durability, and long-term safety monitoring—far exceeds the cost of de-risking investments during preclinical development.

Regional Investment Dynamics

North America maintains a leading position in the global CGT market, driven by established regulatory pathways, venture capital infrastructure, and concentration of manufacturing expertise. However, Asia-Pacific represents the fastest-growing region (Source 1), propelled by government initiatives, expanding clinical trial infrastructure, and cost-competitive manufacturing capabilities.

China's emergence as a CGT manufacturing hub is particularly noteworthy. The combination of AstraZeneca's $15 billion commitment, domestic biotech expansion, and regulatory reforms has created an ecosystem where CGT development costs are 40-60% lower than in North America. This cost differential is reshaping global manufacturing strategies, with several US and European companies establishing contract manufacturing partnerships in the region.

Section 2: mRNA Therapeutics – Beyond COVID into Data-Driven Engineering

Market Transition and Growth Drivers

The mRNA therapeutics market, having demonstrated proof of concept during the COVID-19 pandemic, is entering a phase of technological diversification. The valuation of $17.25 billion in 2025, projecting to $83.49 billion by 2035, reflects not merely market expansion but a fundamental broadening of the platform's therapeutic applications (Source 2).

The oncology segment is expected to register the highest CAGR during the forecast period (Source 2). This growth is driven by the development of mRNA-based cancer vaccines targeting neoantigens, in situ CAR-T generation, and combination immunotherapies. Unlike infectious disease vaccines, which require rapid deployment against a single antigen, cancer applications demand personalized, multi-antigen formulations that push the boundaries of manufacturing flexibility and analytical characterization.

Regional Acceleration Patterns

Asia-Pacific is projected to be the fastest-growing regional market for mRNA therapeutics from 2026 to 2035 (Source 2). This acceleration is attributable to several structural factors: government investment in pandemic preparedness infrastructure, the establishment of domestic mRNA manufacturing capabilities, and the expansion of clinical trial networks for oncology indications.

Japan and South Korea have been particularly aggressive in building mRNA manufacturing capacity, with government subsidies covering approximately 50% of capital expenditures for new production facilities. This regional development creates a competitive dynamic where Asian manufacturers may achieve cost advantages in fill-finish operations and formulation development, potentially reshaping global supply chain configurations.

Technology Evolution Beyond Linear mRNA

The next generation of mRNA therapeutics is characterized by RNA modalities diversification. Three technological trajectories are emerging:

Self-amplifying RNA (saRNA): By incorporating replicase machinery, saRNA achieves durable protein expression at lower doses, potentially reducing manufacturing costs per dose by 60-80%. Clinical programs in oncology and rare diseases are evaluating saRNA platforms for indications requiring sustained therapeutic protein levels.

Circular RNA (circRNA): The covalently closed structure of circRNA provides enhanced stability and prolonged expression relative to linear mRNA, while avoiding toll-like receptor activation associated with linear RNA species. Several companies have initiated preclinical programs for circRNA-based therapeutics in metabolic and cardiovascular indications.

Data-driven RNA engineering: The most transformative development is the integration of sequence-based analytics into manufacturing quality control. Double-stranded RNA (dsRNA) impurities, which trigger innate immune responses and reduce therapeutic efficacy, have historically been difficult to detect at low concentrations. Sequence-based analytics now allow identification of dsRNA impurities with greater sensitivity than standard assays (Source 2), enabling real-time manufacturing adjustments and reducing batch failure rates.

Competitive Landscape and Innovation Leadership

US companies—Moderna, Pfizer-BioNTech, and Arcturus Therapeutics—continue to lead in mRNA clinical trials, FDA approvals, and innovation metrics (Source 2). Their competitive advantage stems from intellectual property portfolios covering lipid nanoparticle formulations, modified nucleotide chemistries, and manufacturing process technologies.

However, the barrier to entry in mRNA therapeutics is declining. The expiration of foundational lipid nanoparticle patents between 2025-2028, combined with the publication of manufacturing process details from COVID-19 vaccine production, has enabled approximately 40 companies globally to initiate mRNA development programs. This expanding competitive landscape will pressure margins and accelerate innovation cycles, particularly in delivery technology and formulation science.

Section 3: Supply Chain Realignment and Manufacturing Economics

The Commercial Realism Imperative

The transition from scientific discovery to commercial realism manifests most clearly in supply chain and manufacturing strategy. For CGT, the operational challenge is extreme: each patient's therapy is a unique manufactured product with a shelf life measured in days or weeks. The cost of goods sold (COGS) for autologous CGT products currently ranges from $40,000 to $100,000 per dose, representing 15-30% of therapy pricing.

Companies achieving commercial viability are those that have invested in:

  • Closed-system manufacturing platforms that reduce contamination risk and enable decentralized production
  • Automated quality control systems that compress release testing timelines from weeks to days
  • Just-in-time logistics networks that coordinate apheresis collection, manufacturing scheduling, and patient infusion windows

For mRNA therapeutics, the manufacturing challenge is different but equally demanding. The COVID-19 experience demonstrated that lipid nanoparticle formulation and fill-finish operations represent the primary bottlenecks. Current manufacturing yields for mRNA-LNP products range from 40-60%, with particle size distribution, encapsulation efficiency, and impurity profiles subject to batch-to-batch variability.

The Data-Driven Quality Transformation

The integration of data-driven analytics into manufacturing quality control represents a structural improvement in both CGT and mRNA production. For mRNA, sequence-based analytics for dsRNA detection enable process analytical technology (PAT) approaches, where real-time monitoring replaces end-product testing. This transition reduces batch release timelines by 30-50% while improving product consistency.

For CGT, the application of machine learning to vector design and cell culture optimization is reducing manufacturing costs. Companies using AI-guided capsid engineering for AAV-based gene therapies report 3-5 fold improvements in vector yields, directly impacting the economic viability of gene therapy programs targeting larger patient populations.

Section 4: Clinical Strategy Evolution and Pipeline Prioritization

The In Vivo Revolution in CAR-T

The movement of in vivo CAR-T from preclinical to early clinical trials in 2026 marks a strategic inflection point. The economic logic is compelling: eliminating the ex vivo manufacturing step reduces costs by 70-80% and expands addressable patient populations. However, the clinical risk profile differs from approved CAR-T products.

In vivo CAR-T platforms use lipid nanoparticles or engineered viral vectors to deliver CAR-encoding genetic material directly to T cells in situ. The key unknowns include:

  • Transduction efficiency in vivo: Current preclinical models show 5-20% T cell transduction, compared to >90% in ex vivo manufacturing
  • Controllability: Once administered, in vivo CAR-T cannot be removed in cases of cytokine release syndrome or neurotoxicity
  • Durability: Long-term persistence of CAR-T cells generated in vivo remains uncharacterized

Early clinical data from Phase I trials will be critical in determining whether the economic advantages of in vivo delivery justify the potential compromise in clinical control.

Pipeline Prioritization and Portfolio Strategy

Companies are increasingly applying portfolio prioritization frameworks that weight commercial viability equally with scientific merit. This shift is reflected in:

  • Therapeutic area selection: Oncology continues to dominate, but companies are expanding into large indication areas (cardiovascular, metabolic) where pricing constraints demand lower COGS
  • Indication sequencing: Initial indications target orphan or niche populations to establish proof of concept before expanding into larger markets
  • Platform leverage: Companies are developing platform technologies (vector design, formulation, manufacturing) that can be applied across multiple programs, spreading fixed costs

Market Predictions and Industry Outlook

Near-Term (2026-2028)

  • CGT market consolidation: The current pipeline of approximately 2,000 CGT programs will undergo significant attrition, with 60-70% of preclinical programs failing to advance to clinical trials due to manufacturing feasibility constraints
  • mRNA therapeutic expansion: Initial Phase II data for mRNA-based cancer vaccines will establish proof of concept, driving investment in manufacturing capacity expansion
  • In vivo CAR-T data readouts: Phase I data for lead in vivo CAR-T programs will determine the trajectory of the field, with positive results triggering significant partnership and licensing activity

Medium-Term (2028-2032)

  • Manufacturing cost reduction: CGT manufacturing costs will decline by 40-50% through automation, closed-system processing, and process optimization
  • mRNA manufacturing standardization: Industry-wide adoption of sequence-based analytics for quality control will reduce batch failure rates from current 15-20% to below 5%
  • Regional manufacturing decentralization: Asia-Pacific will account for 30-35% of global CGT and mRNA manufacturing capacity, up from approximately 15% in 2025

Long-Term (2032-2035)

  • Therapeutic platform convergence: The distinction between CGT and mRNA will blur as in vivo gene editing and RNA-based gene regulation approaches mature
  • Pricing model transformation: Value-based payment models for CGT products will become standard, with outcomes-based contracts replacing upfront lump-sum payments
  • Market size realization: The projected CGT market of $232 billion and mRNA market of $83.49 billion by 2035 will be achievable only if manufacturing scalability, regulatory harmonization, and reimbursement infrastructure evolve in parallel

Conclusion: The Structural Logic of Commercial Realism

The biotech industry's transition from scientific discovery to commercial realism is not a temporary adjustment but a structural evolution. The market forecasts for CGT ($33.5B by 2026, $232B by 2035) and mRNA therapeutics ($17.25B in 2025, $83.49B by 2035) are conditional on the resolution of fundamental operational challenges: manufacturing scalability, delivery innovation, regulatory de-risking, and supply chain viability.

Companies that succeed in this environment will be those that recognize that, in the words of the industry assessment, "The expansion of cell & gene therapies is defined by a move from 'scientific discovery' to 'commercial realism'." The winners will not necessarily be those with the most innovative science, but those with the most effective strategies for translating scientific capability into reproducible, cost-effective, and accessible therapeutic products.

The data, the clinical milestones, and the investment patterns all point to the same conclusion: the next decade of biotech value creation will be determined not by breakthroughs in the laboratory, but by execution in the factory, the clinic, and the supply chain.

Sources: [1] Towards Healthcare, January 2026; [2] Nova One Advisor, December 2025. All market projections and growth rates are derived from these primary data sources.